The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA

Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA

September 29, 2017 • By Michael Erman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—Makers of fast-acting opioids will have to fund voluntary training for healthcare professionals who prescribe the drugs, including education on safe prescribing practices and non-opioid alternatives, the course  said on Thursday.

You Might Also Like
  • FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse
  • FDA Expands Safety Measures for Immediate Release Opioids
  • FDA Names Drugmakers Potentially Acting to Delay Cheap Generics

The FDA sent letters to 74 manufacturers of immediate-release opioids, notifying them that they will have to fund the development of courses for doctors, nurses and pharmacists, FDA Commissioner Scott Gottlieb said in a statement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

President Donald Trump and Gottlieb have promised to reduce opioid abuse in the United States, which has become a public health crisis that kills more than 100 Americans daily.

Makers of extended-release and long-acting formulations of the painkillers, which are more easily abused, are already required to pay for the training.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

While the training will be offered as voluntary continuing education for healthcare professionals, the agency is also considering some form of mandatory education on opioids.

About 90 percent of all opioid pain medications prescribed in the United State – around 160 million prescriptions a year – are for the fast-acting formulations, the FDA said.

The FDA asked Endo International Inc to pull its long-lasting opioid painkiller, Opana ER, from the market in June, after a panel of advisers concluded that the drug’s benefits did not outweigh the risks of misuse.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

According to the U.S. Centers for Disease Control and Prevention, opioids were involved in more than 33,000 U.S. deaths in 2015, the latest year for which data is available, and estimates show the death rate has continued rising.

On Thursday, Washington state sued OxyContin maker Purdue Pharma LP, becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for the opioid addiction crisis.

 

Filed Under: Drug Updates, Education & Training Tagged With: course funding, fast-acting opioids, opioid drug companies, U.S. Food and Drug Administration (FDA), voluntary training

You Might Also Like:
  • FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse
  • FDA Expands Safety Measures for Immediate Release Opioids
  • FDA Names Drugmakers Potentially Acting to Delay Cheap Generics
  • U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.